AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Preclinical development program initiated for new HIV vaccine candidate.
2003 DEC 3 - (NewsRx.com & NewsRx.net) -- The Immune Response Corporation (IMNR) has initiated a preclinical development program with IR103, a new vaccine candidate for the prevention and treatment of HIV, the virus that causes AIDS.
The program is based on the promising results obtained from proof-of-concept studies with IR103, and is designed to provide data that would support regulatory filings for phase I clinical studies.
IR103 combines Amplivax, an adjuvant being developed by Hybridon, Inc. (HYBN), to enhance the immune response to a vaccine antigen, with the HIV-1 Immunogen technology employed in Remune, an immune-based therapeutic vaccine currently being evaluated in phase II clinical trials by The Immune Response Corporation for the treatment of HIV infected individuals.
"We are very pleased to be moving forward with the IR103 development program," said Georgia Theofan, PhD, vice president of clinical development at The Immune Response Corporation.
"IR103 demonstrated significant HIV- specific cell mediated immune responses in early preclinical studies. These data confirm initial results indicating that the combination of our vaccine antigen and immunomodulatory adjuvants such as Amplivax can have a strong effect on the overall immune response.
"Based on ...
- The Immune Response Corporation Announces Acquisition Of T Cell Receptor...
- Press release article from: PR Newswire December 13, 1999 700+ words
...PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR) today...intellectual property to The Immune Response Corporation, in exchange for cash, stock and royalties. The Immune Response Corporation owns additional TCR...
- Connetics and XOMA Sell T Cell Receptor Technology to the Immune Response...
- Press release article from: Business Wire December 13, 1999 700+ words
...intellectual property to The Immune Response Corporation (IRC, Nasdaq:IMNR...stock and royalties. The Immune Response Corporation owns additional TCR...and common stock of The Immune Response Corporation, as well as royalties...
- THE IMMUNE RESPONSE CORPORATION'S LICENSED B CELL LYMPHOMA TECHNOLOGY RECEIVES...
- Press release article from: PR Newswire April 25, 1996 700+ words
...PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR) announced...exclusively licensed to The Immune Response Corporation. This technology provides...Kimmel Cancer Center. The Immune Response Corporation is a biopharmaceutical...
- THE IMMUNE RESPONSE CORPORATION'S LICENSED TECHNOLOGY SHOWN TO ERADICATE BRAIN...
- Press release article from: PR Newswire April 2, 1996 700+ words
...PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR) today...collaborative effort between The Immune Response Corporation and SKCC has already...Executive Officer of The Immune Response Corporation. "We believe this technology...
- THE IMMUNE RESPONSE CORPORATION COMPLETES ENROLLMENT OF PHASE II CLINICAL TRIAL...
- Press release article from: PR Newswire March 12, 1996 700+ words
...PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR) announced...executive officer of The Immune Response Corporation. "We are excited about...debilitating disease." The Immune Response Corporation is a biopharmaceutical...
- THE IMMUNE RESPONSE CORPORATION'S LICENSED TECHNOLOGY RECEIVES U.S. PATENT
- Press release article from: PR Newswire March 14, 1996 700+ words
...PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR) announced...exclusively licensed to The Immune Response Corporation. This newly patented...therapy programs. The Immune Response Corporation is a biopharmaceutical...
- The Immune Response Corporation Postpones Follow-on Public Offering of Common...
- Press release article from: PR Newswire August 7, 1996 700+ words
...PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR) announced...executive officer of The Immune Response Corporation. "Immune Response has...less volatile." The Immune Response Corporation is a biopharmaceutical...
- The Immune Response Corporation and NovaRx Corporation Announce Revision of...
- Press release article from: PR Newswire September 8, 2004 700+ words
The Immune Response Corporation , a biopharmaceutical company...agreement to transfer all of The Immune Response Corporation's in-licensed development...NovaRx agreed to pay The Immune Response Corporation the total sum of $1,050...
Source: HighBeam Research, Preclinical development program initiated for new HIV vaccine...